No, 4-AcO-DMT is not legal in the United States. The compound is not listed by name in the federal Controlled Substances Act, but under the Federal Analogue Act it is treated as a Schedule I substance because of its close chemical and pharmacological relationship to psilocin. Possessing, selling, or manufacturing it carries the same federal penalties as any other Schedule I drug, and a handful of states schedule it by name on top of that.
Why Federal Law Treats It as Schedule I
The government does not have to list every new psychoactive compound by name to prosecute someone for it. Under 21 U.S.C. § 813, any controlled substance analogue intended for human consumption is treated as a Schedule I substance for purposes of federal criminal law.
The definition sits in 21 U.S.C. § 802(32)(A). A substance qualifies if its chemical structure is substantially similar to a Schedule I or II drug, and it either produces a substantially similar effect on the central nervous system or is represented as doing so.1Office of the Law Revision Counsel. 21 USC 802 – Definitions
4-AcO-DMT fits this framework cleanly. Psilocin (4-hydroxy-DMT) is a Schedule I hallucinogen under federal law.2Drug Enforcement Administration. Controlled Substances by DEA Drug Code Number 4-AcO-DMT is the acetylated form of psilocin, differing by a single acetyl group, and once ingested the body metabolizes it into psilocin itself. It produces essentially the same experience. Compared to analogue cases where the structural relationship is more attenuated, this one is about as straightforward as it gets.
Do “Not for Human Consumption” Labels Help
The Analogue Act only applies when a substance is “intended for human consumption.” That language is why online vendors label synthetic tryptamines as “research chemicals” or stamp packages with “not for human consumption.” The label rarely protects anyone.
Courts weighing intent can look at the marketing, the price compared to legitimate research chemicals, whether the substance moved through normal commercial channels, and whether the seller knew or should have known buyers would ingest it.3Office of the Law Revision Counsel. 21 USC 813 – Treatment of Controlled Substance Analogues A powder sold in single doses at recreational prices, advertised alongside trip reports, will look like it was meant to be consumed no matter what the packet says.
The Supreme Court reinforced this in McFadden v. United States. The defendant sold bath salts with labels stating “not for human consumption” and disclaiming any similarity to controlled substances. The Court held the government must prove the defendant knew the substance was controlled or intended to be consumed, but did not treat the label as a shield.4Justia. McFadden v. United States, 576 US 186
Federal Penalties
Because 4-AcO-DMT is treated as Schedule I, the same penalty statutes that reach psilocin, heroin, and LSD reach it too. The stakes depend on whether the conduct is simple possession or distribution.
Simple Possession
A first offense for simple possession of any Schedule I substance carries up to one year in prison and a minimum fine of $1,000. A second offense raises the range to 15 days to two years with a minimum $2,500 fine. Three or more prior drug convictions push the floor to 90 days and the ceiling to three years, with a minimum $5,000 fine.5Office of the Law Revision Counsel. 21 USC 844 – Penalties for Simple Possession
Distribution and Manufacturing
Selling or manufacturing is far more serious. For a Schedule I substance where no specific quantity threshold is triggered, a first offense can bring up to 20 years in federal prison and a fine of up to $1 million for an individual. If someone dies or suffers serious bodily injury from using the substance, the mandatory minimum jumps to 20 years and the maximum becomes life imprisonment.6Office of the Law Revision Counsel. 21 USC 841 – Prohibited Acts A Federal sentencing guidelines make substantial prison time the norm.
State Laws Add Another Layer
State drug laws do not always mirror federal classifications, and they can create exposure even where federal enforcement is unlikely. States generally handle 4-AcO-DMT one of three ways.
Some schedule it explicitly. Alabama, for example, lists 4-AcO-DMT as a controlled substance under state law. Prosecutors there do not need an analogue theory; possessing the named compound is enough.
Others rely on state analogue statutes, which apply “substantially similar” logic at the state level. Wording varies, and state courts sometimes read the standard differently than federal courts do.
A minority of states have neither an explicit listing nor a robust analogue statute. That does not make possession safe, because federal law still applies everywhere. Because state schedules change frequently, verifying your own state’s current controlled substance list is worth the effort.
Psilocybin Decriminalization Does Not Cover It
The growing movement to decriminalize or create regulated access for psilocybin has led some people to assume 4-AcO-DMT benefits from the same reforms. It does not. Every major decriminalization measure passed so far is limited to naturally occurring substances — psilocybin-producing mushrooms and fungi — and excludes synthetic compounds.
Colorado’s Natural Medicine Health Act is restricted to “plants or fungi” containing the covered substances and does not permit synthetic versions. Oregon’s supervised psilocybin services program authorizes only psilocybin-producing mushrooms and fungi products administered through licensed service centers. A synthetic prodrug like 4-AcO-DMT falls outside both frameworks, no matter how pharmacologically similar it is to natural psilocybin.
This matters because 4-AcO-DMT is often sold in products marketed as “mushroom edibles” or “psilocybin chocolates.” Buying one of those in a state that decriminalized natural psilocybin gives you no additional legal protection when the active ingredient is actually synthetic 4-AcO-DMT.
The Narrow Research Exemption
The one exception is authorized scientific research. The DEA issues specific registrations allowing researchers to possess and study Schedule I substances and their analogues under tightly controlled conditions. Approval requires a detailed research protocol, institutional review, and strict inventory and security measures.7Drug Enforcement Administration. Researchers Manual 2022 Edition The exemption exists for institutions running pharmacological studies. It has no practical relevance for individual possession or personal use.